Psychiatr. praxi. 2023;24(3):165-169 | DOI: 10.36290/psy.2023.031

Clozapine and Parkinson's disease related psychosis

MUDr. Katarína Ďurčová Typčuková1, MUDr. Marcela ©oltýsová1, 2, MUDr. Mária Holá1, 3, MUDr. Ján Necpál1, 3, 4
1 Centrum pre liečbu parkinsonizmu a extrapyramídových porúch, Nemocnica Zvolen, a. s., Zvolen
2 Fyziologický ústav, Lekárska fakulta Univerzity Komenského, Bratislava
3 Neurologické oddelenie, Nemocnica Zvolen, a. s., Zvolen
4 II. neurologická klinika, Lekárska fakulta Univerzity Komenského, Bratislava

Parkinson´s disease related psychosis is a serious neuropsychiatric complication of Parkinson´s disease. According to evidence-based medicine, the gold standard in the treatment is treatment with clozapine, an atypical antipsychotic drug with multireceptor properties and low risk of extrapyramidal side effects. Although clozapine seems to be very effective, it is quite underused, mainly due to the fear of developing agranulocytosis. This fear leads commonly to clozaphobia among physicians. The review brings basic facts about clozapine and management of Parkinson´s disease related psychosis.

Keywords: clozapine, Parkinson's disease related psychosis, clozaphobia, agranulocytosis.

Accepted: October 9, 2023; Published: October 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďurčová Typčuková K, ©oltýsová M, Holá M, Necpál J. Clozapine and Parkinson's disease related psychosis. Psychiatr. praxi. 2023;24(3):165-169. doi: 10.36290/psy.2023.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vančíková J. Psychiatrické poruchy pri Parkinsonovej chorobe. Psychiatria­‑psychoterapia­‑psychosomatika. 2012;3-4:72-6.
    2. Patarák M. Psychóza spojená s Parkinsonovou chorobou. Česká a slovenská psychiatrie. 2014;110(4):210-4.
    3. Patarák M, Necpál J. Psychóza pri Parkinsonovej chorobe indukovaná dopamínovým agonistom. Psychiatria pre prax. 2011;12(2):50-2.
    4. Taddei RN, Cankaya S, Dhaliwal S, et al. Management of Psychosis in Parkinson's diesease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons, DiS. 2017:3256542. Go to original source... Go to PubMed...
    5. Black KJ. Treatment of Parkinsons disease psychosis. Med. Int. Rev. 2017;27(109):266-71.
    6. Thames BH, Ondo WG. Clozapine: Efficacy for Parkinson Disease psychosis in patients refractory to pimavanserin. Parkinsonism Relat Disord. 2023;109:105356. Go to original source... Go to PubMed...
    7. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39-60. Go to original source... Go to PubMed...
    8. Pečeňák J, Kořînková V, et al. Psychofarmakológia. 1. vyd. Wolters Kluwer, s. r. o.; 2016: 291-297.
    9. Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15(1):33-48. Go to original source...
    10. Khokhar JY, Henricks AM, Sullivan EDK, et al. Unique Effects of Clozapine: A Pharmacological Perspective. Adv Pharmacol. 2018; 82:137-162. Go to original source... Go to PubMed...
    11. Yuen JWY, Kim DD, Procyshyn RM, et al. A Focused Review of the Metabolic Side­‑Effects of Clozapine. Front Endocrinol (Lausanne). 2021;12:609240. Go to original source... Go to PubMed...
    12. Lappin JM, Wijaya M, Watkins A, et al. Cardio­‑metabolic risk and its management in a cohort of clozapine­‑treated outpatients. Schizophr Res. 2018;199:367-373. Go to original source... Go to PubMed...
    13. Tso G, Kumar P, Jayasooriya T, et al. Metabolic monitoring and management among clozapine users. Australas Psychiatry. 2017;25(1):48-52. doi: 10.1177/1039856216665282. Go to original source... Go to PubMed...
    14. Divac N, Stojanović R, Savić Vujović K, et al. The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease. Behav Neurol. 2016;2016:4938154. Go to original source... Go to PubMed...
    15. Parkinson's disease in adults. NICE guideline [NG71] [Internet]. [cited 2023 Jul 16] 2017. Available from: https://www.nice.org.uk/guidance/ng71/chapter/Recommendations#managing­‑and­‑monitoring­‑impulse­‑control­‑disorders­‑as­‑an­‑adverse­‑effect­‑of­‑dopaminergic­‑therapy.
    16. Parkinson Study Group. Low­‑dose clozapine for treatment of drug­‑induced psychosis in Parkinson's disease. N Engl J Med. 1999;340(10):757-63. Go to original source... Go to PubMed...
    17. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo­‑controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-95. Go to original source... Go to PubMed...
    18. Zhang H, Wang L, Fan Y, et al. Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta­‑analysis. Neuropsychiatr Dis Treat. 2019;15:2137-49. Go to original source... Go to PubMed...
    19. Mayerová M, Horská K, Ustohal L. Klozapin: moderní antipsychotikum s dlouhou tradicí. 1. vyd. Praha: Galen; 2021: 202 pp.
    20. Hack N, Fayad SM, Monari EH, et al. An eight­‑year clinic experience with clozapine use in a Parkinson's disease clinic setting. PloS One. 2014;9(3):e91545. Go to original source... Go to PubMed...
    21. Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration. Neurology. 1997;49(6):1587-90. Go to original source... Go to PubMed...
    22. Leponex. Súhrn charakteristických vlastností lieku. [Internet]. [cited 2023 Jul 16] Available from: https://www.sukl.sk/hlavna­‑stranka/slovenska­‑verzia/pomocne­‑stranky/detail­‑lieku?page_id=386 & lie_id=03617.
    23. Cetin M. Clozaphobia: Fear of Prescribers of Clozapine for Treatment of Schizophrenia. Bulletin of Clinical Psychopharmacology. 2014;24(4):295-301. Go to original source...
    24. Friedman JH. Clozapine Is Severely Underused in Parkinson's Disease Patients. Mov Disord Clin Pract. 2022;9(8):1021-4. Go to original source... Go to PubMed...
    25. Kmoch V. Monitorovací systém LEX­‑SYS. Psychiatr. prax. 2006;1:34.
    26. Alphs LD, Anand R. Clozapine: the commitment to patient safety. J Clin Psychiatry. 1999;60(Suppl 12):39-42.
    27. Masopust J, Kopeček M, Protopopová D. Sledování tělesného zdraví u pacientů se závaľnými neorganickými duąevními poruchami (psychózy, bipolární porucha, depresivní porucha) [Internet]. Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. Update 2020. [cited 2023 Jul 16] Available from: https://postupy­‑pece.psychiatrie.cz/obecna­‑psychiatrie/sledovani­‑telesneho­‑zdravi.
    28. Lutz UC, Sirfy A, Wiatr G, et al. Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders. Eur J Clin Pharmacol. 2014;70(12):1471-6. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.